In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Biotech CEOs: Can Scientist-Founders Remain In Charge?

Founder-CEOs do not typically remain at the helm as biotechs mature. Exceptions to that rule are multiplying, though, especially in Europe as companies aim directly for Nasdaq.

C-Suite Speaks Business Strategies Leadership

Leading In Product Development Means Planning For All Eventualities

What is the cost of an adverse event, and the resulting safety action for a medical device that is already on the market? It is the kind of question that no company with products on the market wants to have to confront, but it is also one they know they should plan for, says the design consultancy and innovation organization NCS Lab srl.

Manufacturing Market Intelligence Research and Development Strategies

Israel Looks To Nurture New Leaders For Burgeoning Biotech Sector

While Israel has not wanted for early-stage scientific excellence, leading lights in the country's biotech space are working to create an ecosystem where clinical, regulatory and managerial expertise can develop.

Growth Business Strategies Israel

The Many Paths To Biotech CEO

There is no single path toward becoming a CEO. The job requires many different skills, often concurrently: sharp analytical capabilities, strategic thinking, clear communication with multiple audiences, curiosity and perseverance. It demands strong leadership but also humility, and a willingness to acknowledge mistakes and knowledge gaps.

C-Suite Speaks Business Strategies Leadership
Advertisement

Recent Tweets from In Vivo


Roundtable: How to Improve R&D with AI and Machine Learning

Register your interest for this upcoming roundtable (June 4th, 2:50 – 3:30 pm) where panelist will look at the opportunities AI and machine learning offer to help you record in real-time your laboratory activities, access results more easily, reduce experimental error, improve R&D efficiency and shorten product development timelines. Seats are limited, register your interest today!

Register
Advertisement

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

TISSIUM CEO’s Vision Is To Make The Tissue Recon Label Stick

Christophe Bancel, CEO of French medtech innovator TISSIUM, has made a career in various parts of the health care products industry, identifying business opportunities, founding, directing and leading ventures, and planning for contingencies. The ex-Serono and UCB executive, who has had many other postings, is now testing his adaptability and leadership qualities by bringing a versatile class III synthetic polymer device into key markets.

Business Strategies C-Suite Speaks

Growing And Innovating As A CDMO Business

Frank Mathias, CEO of Rentschler Biopharma, a contract development and manufacturing organization, talks to In Vivo about the company’s new corporate strategy and why he allowed 18 months to prepare that plan for delivery.

C-Suite Speaks Business Strategies

Medtech Innovators Must Find The Right Problems To Solve

In the world of medtech innovation, investment and market access, commentators are seeing a maturing attitude to risk, more readiness to address workflows and greater awareness of being on the ball in a regulatory sense. Senior executives from consultancy firm Technology Commercialization Group (TCG) give In Vivo their take on what is behind these changes.

Business Strategies Growth

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

The Eye Travels Wide: ProQR’s Bid For Leadership In The Genetics Of Sight

How did a youthful vendor of IT services, faced with a personal exposure to crippling illness, attract some of the best minds in biotech to launch a company with a then-untested RNA technology that today is a contender for leadership in the rarified space of inherited retinal disease? The answer may lie in the ambitiously definitive name that 36-year-old founder Daniel de Boer gave to his enterprise with a mission: ProQR – an active synonym for finding cures.

C-Suite Speaks Gene Therapy

Philips Plugs Into Value-Based Needs On Delirium In The ICU

Delirium in the ICU is a major problem for post-surgery patients and a major cost for health care systems. Philips has developed a solution that offers an alternative to the sedative-based approach, use of which is often a risk in ICU patients.

Innovation Medical Device

R&D Meets The Crowdscape: BioMed X Looks Outside For Insight

It is a cliché to say that pharma science loves to collaborate – the hard thing is that leaky decision framework by which good ideas do not get executed.

Innovation C-Suite Speaks

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

Titans Of Pharma 2019: An Infographic Snapshot Of The Industry’s Leaders

In 2018, the 15 biggest pharma companies paid their CEOs $256m in total compensation, 2% more than they received in 2017. Find out who got paid the most, how much R&D leaders received and how median employee pay measured up, while comparing company performance.

Business Strategies Leadership

Rare Is The Definition Of Leadership: The Lasting Legacy Of Henri Termeer

In a recent interview, ProQR’s founder Daniel de Boer cited the enormous impact that fellow Dutch businessman Henri Termer played in getting his fledging biotech start-up off the ground – especially given the circumstances.  Some 10 years ago, the then twenty-something budding biotech entrepreneur crossed the Atlantic on a chance that Termeer would answer what amounted to an unscheduled desk-knock at the rare disease pioneer’s office at Genzyme HQ in Cambridge, MA.  He did – and the rest is history.

Leadership Strategy

New AdvaMed Chair Lobo: Devices Has A Good Story To Tell

A whirlwind two-year stint as chair of the US medtech industry association, AdvaMed, came to end this month for CVRx’e energetic CEO Nadim Yared. Incoming chair, Stryker’s Kevin Lobo, comes from an altogether much larger concern, but he will continue Yared’s legacy of supporting SMEs, as well as bringing his own agenda to the role.

Leadership Business Strategies

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

Beyond The Watershed: Gene Therapy Investment And Promise

Janet Lambert, CEO of the Alliance of Regenerative Medicines recently spoke to In Vivo about the tremendous levels of investment the cell and gene therapy industries are attracting, as well as reasons why Europe excels at incubating advanced product development.

Gene Therapy Regenerative Medicine

Podcast: Innovations In Market Access

In Vivo welcomes Indranil Bagchi, SVP of global value and access at Novartis Oncology, and Srikant Vaidyanathan, senior partner and managing director of the Boston Consulting Group, onto the podcast to discuss the future of market access as a function in the biopharma industry.   

 

Market Access Reimbursement

Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition

It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?

Market Access Pharmacy Benefit Management

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

Biopharma Quarterly Dealmaking Statistics, Q1 2019

First quarter biopharma financing, at $17.96bn, demonstrated a 65% increase over Q4 2018. The $92bn in total M&A activity was led by Bristol-Myers Squibb's $74bn buy of top-tier public biotech Celgene. At $39.4bn in total potential deal value, alliance dealmaking started off 2019 strong, with most of the top partnerships in modalities outside the recently popular areas of immune checkpoint inhibitors or CAR-T therapies.

Market Intelligence BioPharmaceutical

Deals In Depth: March 2019

Alexion signed two $600m-plus alliances, with Zealand Pharma and Affibody, that made it into the top five deals by value. Thermo Fisher grew its capabilities in cell and gene therapy manufacturing by acquiring Brammer Bio for $1.7bn. A $3.5bn private placement by AstraZeneca boosted pharma financing.

Deals Market Intelligence

Deals Shaping The Medical Industry, May 2019

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced April 2019.

Deals Financing
UsernamePublicRestriction

Register

Advertisement